Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V (clinicaltrials.gov) - Oct 16, 2026 - P2 | N=81 | Terminated | Sponsor: Novartis Pharmaceuticals | N=240 ➔ 81 | Trial completion date: Sep 2028 ➔ Oct 2026 | Recruiting ➔ Terminated; The decision to conclude the study after Part 1 LPLV is based on strategic considerations by the Sponsor.
Enrollment change • Trial completion date • Trial termination • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|